To improve human health and save lives by accelerating the development of safe, effective medicines.
Liaison Advisory Member – Non-voting
Liaison Advisory Member – Non-voting
Chief Technology Officer
Chief Operating Officer
President and CEO
Executive Director, Patient Reported Outcome Consortium
Executive Director, Critical Path to TB Drug Regimens Regulatory Science Consortium
Chief Science Officer; Executive Director, Multiple Sclerosis Outcome Assessments Consortium
Director, Electronic Patient-Reported Outcome Consortium
Director, Clinical Pharmacology
Executive Director, Predictive Safety Testing Consortium
Executive Director, Coalition Against Major Diseases
Director, Regulatory Strategy & Submissions
President Emeritus; Former Chairman of the Board
Dr. Lyle Bootman has served as Dean of The University of Arizona College of Pharmacy since 1987. Dr. Bootman is Professor of Pharmacy, Medicine and Public Health, and a fellow of several professional associations, including the American Pharmacists Association, American Association of Pharmaceutical Scientists, and the American College of Apothecaries. He is the Founding and Executive Director of the University of Arizona Center for Health Outcomes and PharmacoEconomic (HOPE) Research, one of the first such centers developed in the world. He is former President of the American Pharmacists Association and President Emeritus of the Pharmacy & Therapeutics Society.
Dr. Bootman received his pharmacy education at the University of Arizona and his doctorate at the University of Minnesota. He completed a clinical pharmacy residency at the National Institutes of Health, and received an honorary doctorate from the University of the Sciences in Philadelphia. He has received numerous outstanding scientific achievement awards, most notably from the American Association of Pharmaceutical Scientists and the Academy of Pharmaceutical Science and Research. Currently, he serves on several prestigious boards, including Critical Path Institute, Research Corporation Technologies, CMR Institute and Madeira Therapeutics.
Dr. Craig Brater serves as Vice President of Indiana University with responsibilities for the Life Sciences and Dean of the IU School of Medicine. Upon joining Indiana University in 1986, he established the Division of Clinical Pharmacology in the Department of Medicine, creating a partnership with Purdue University, which he has continued to advance over the past 20 years. In 1990, Dr. Brater became chairman of the Department of Medicine, the largest department at Indiana University. In 2000, he was selected to be the ninth Dean of the IU School of Medicine. He serves as a board member of Indiana University Health, board and executive committee member of BioCrossroads and chairman of the board of Fairbanks Institute.
Dr. ShaAvhrée Buckman is currently the Director of the Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA). OTS is comprised of the Office of Biostatistics and the Office of Clinical Pharmacology. OTS provides oversight to CDER research involving human subjects as well as CDER regulatory science research. OTS is responsible for providing coordination for Critical Path initiatives across CDER in partnership with individual CDER offices.
Dr. Buckman served as Deputy Director for OTS prior to accepting the position as Director. Before joining OTS, Dr. Buckman served as a medical team leader in the Division of Pediatric Drug Development, Office of Counter Terrorism and Pediatric Drug Development, CDER. Dr. Buckman received her medical degree and doctorate (with an emphasis on molecular cell biology) from the Washington University School of Medicine. Dr. Buckman completed Pediatric specialty training at Baylor College of Medicine.
Dr. Peter Corr is Co-founder and General Partner of Celtic Therapeutics Management LLLP. Dr. Corr retired from Pfizer, Inc., where he was Senior Vice President for Science and Technology. He also headed worldwide pharmaceutical research and development for Pfizer. Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development, and President, Worldwide Development. He also served as Senior Vice President, Discovery Research, at Monsanto/Searle, and then President of Pharmaceutical Research and Development at Warner Lambert/Parke-Davis. Dr. Corr, who received his doctorate from Georgetown University School of Medicine, spent 18 years as a researcher in molecular biology and pharmacology at Washington University in St. Louis. Missouri.His research has been published in more than 160 scientific manuscripts. He is a trustee of the Joyce Theatre Foundation in New York City, and a member of the National Academies’ Institute of Medicine (IOM) Committee on Conflict of Interest in Medical Research, Education, and Practice, the IOM Forum on Drug Discovery, Development, and Translation, and the IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development.
M. Wainwright Fishburn, Jr. is a founding partner of Cooley LLP’s San Diego office and leads the firm’s Wireless Health Group. Mr. Fishburn is an active community leader and has shaped many industry organizations. He is Chairman of the Sanford-Burnham Institute for Medical Research and serves on the Board of the Wireless-Life Sciences Alliance. He is on the Board of the Critical Path Institute, an independent institute created in part by the FDA, dedicated to improving the regulatory path for innovative medical therapies. He is also a founding member of the Corporate Directors Forum, as well as BIOCOM, where he serves as a member of the Executive Committee.
Mr. Fishburn is a co-founder of six companies, two of which are public. Prior to law school, he worked in the corporate environment assisting with the divestiture of 12 operating companies. He completed post-graduate work as a Senior Fellow at the Australian National University and received his J.D. degree from the University of California, Hastings College of the Law. He has served as President of the Hastings Board of Governors.
James C. Greenwood is President and CEO of the Biotechnology Industry Organization (BIO) in Washington, D.C., which represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Since his appointment in January of 2005, he has markedly enhanced the trade association’s capacity for increasing both its staff and budget by nearly 50 percent. BIO is now a world-class advocacy organization playing a leading role in shaping public policy on a variety of fronts critical to the success of the biotechnology industry at the state and national levels as well as internationally. Mr. Greenwood represented Pennsylvania’s Eighth District in the U.S. House of Representatives from January 1993 through January 2005. A senior member of the Energy and Commerce Committee, he was widely viewed as a leader on health care and the environment. From 2001 to 2004, Mr. Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full committee’s vast jurisdiction. He led hard-hitting investigations into corporate governance at Enron, Global Crossing and WorldCom; terrorist threats to our nation’s infrastructure; and waste and fraud in federal government agencies.
Prior to his election to Congress, Mr. Greenwood served six years in the Pennsylvania General Assembly (1981-86) and six years in the Pennsylvania Senate (1987-1992). Mr. Greenwood graduated from Dickinson College in 1973 with a BA in Sociology. From 1977 until 1980, he worked as a caseworker with abused and neglected children at the Bucks County Children and Youth Social Service Agency. Mr. Greenwood is married with three children and resides in Upper Makefield, Pennsylvania.
Mr. Jeffery Jacob is the principal of Tucson Pharma Ventures LLC, an Arizona-based biopharmaceutical development, consulting and investment firm. Throughout his career, Mr. Jacob has created technology-based startup companies and supported the expansion of existing companies in both the physical and life sciences. He currently serves as the CEO of Cancer Prevention Pharmaceuticals, a development stage company pioneering preventative therapeutics in oncology. Mr. Jacob is a founding board member and previously served as the Chief Program Officer of Critical Path Institute (C-Path); he was responsible for creating C-Path’s business plan and initial programs. On behalf of C-Path, Mr. Jacob currently serves as Interim President of the National Biosignature Laboratory initiative, which aims to create analytical standards for biomarkers and assays used in healthcare research.
Between 1987 and 2004, Mr. Jacob worked with Research Corporation Technologies (RCT), most recently as its Senior Vice President. During this time, he led the transformation of the company from a patent development and licensing organization to an early stage technology incubation and venture development firm. Mr. Jacob has a master’s degree in engineering and a master’s degree in Technology and Policy from the Massachusetts Institute of Technology.
Dr. Michael Kasser is the CEO and President of Holualoa Companies, a real estate investment company with interests in residential and commercial real estate in the Northeast, Southwest, Hawaii and Europe. Dr. Kasser started at Holualoa in 1985. His previous experience includes positions as financial analyst with WR Grace & Co.; as President of Technopulp, Inc., a pulp and paper consultant, and as CEO of Booher Lumber Company. Dr. Kasser’s community activities have included: Chairman of the Salary Commission for the County of Hawaii; in addition, he has been a member of the board of the Kona Hawaii Family MCA, the Aloha Performing Arts Center, the American Hungarian Foundation, the National Museum of Women in the Arts, and the Kasser Art Foundation; and is presently a trustee and/or board member of the University of Arizona Foundation, the College of Science at the University of Arizona, the Tucson Museum of Art and The Metropolitan Museum of Art Department of Scientific Research Visiting Committee.
His outside business activities have included board memberships of: CyraCom, Inc., a language interpretation company; Protein Sciences, Inc., a biotech company; and West Maricopa Combine, Inc., a water company. He has also served as an Educational Counselor for M.I.T. and as a member of its Corporation Development Committee, and is presently a member of the M.I.T. Music and Theatre Arts Visiting Committee. Dr. Kasser has a bachelor of science degree and master’s of science in Chemical Engineering from M.I.T., a doctorate of Engineering from the University of Grenoble (France) and an MBA from Harvard Business School. He is fluent in French, German, Spanish, Italian and Hungarian.
Mr. Shaun Kirkpatrick is president and chief executive officer of Research Corporation Technologies (RCT) in Tucson, Arizona, and serves on the company’s Board of Directors. Kirkpatrick oversees RCT’s BioVentures investment portfolio and technology development and licensing activities in North America, Europe and Australia. In addition to overseeing company-wide matters, he manages a portfolio of technology investments and companies in the biomedical sciences for RCT. He also plays an active role in creating new companies around novel therapeutics and biomedical platforms, and serves as executive management during the incubation phase. Mr. Kirkpatrick received his master’s degree in international economics and science/technology in international economics from Johns Hopkins University School of Advanced International Studies in Washington, D.C., and Bologna, Italy.
He graduated summa cum laude from the University of Arizona in Tucson with dual undergraduate degrees in economics and ecology/evolutionary biology. He also studied at the London School of Economics, the University of Kansas and Eastern Michigan University. RCT is a technology investment and management company that provides early/seed-stage funding and development for promising biomedical companies and technologies originating in the world’s universities and research institutions.
Mr. James Kolbe is a Senior Transatlantic Fellow for the German Marshall Fund of the United States. Mr. Kolbe advises on trade matters as well as issues of effectiveness of US assistance to foreign countries, on US-EU relationships and on migration and its relationship to development. He is co-chair of the Transatlantic Taskforce on Development with Gunilla Carlsson, the Swedish Minister for International Development Cooperation. He also serves as an adjunct Professor in the College of Business at the University of Arizona, and on a part-time basis as strategic consultant with McLarty Associates. For 22 years, Mr. Kolbe served in the United States House of Representatives, elected for 11 consecutive terms (1985 to 2007). He represented the eighth Congressional district, comprising the southeastern part of Arizona with Tucson as the main population center.
While in Congress, Mr. Kolbe served for 20 years on the Appropriations Committee of the House of Representatives. He was Chairman of the Treasury, Post Office and Related Agencies subcommittee for four years, and for the last six years in Congress, he chaired the Foreign Operations, Export Financing and Related Agencies subcommittee. Mr. Kolbe graduated from Northwestern University with a bachelor’s degree in Political Science and earned an MBA from Stanford University with a concentration in economics.
Mr. Rick Myers was named to the board after serving as Chief Operating Officer of C-Path, a position he held from January 2009 through March 2012. Rick is starting his third year of an eight-year term with the Arizona Board of Regents and currently serves as Chair. Prior to C-Path, Mr. Myers retired from IBM Corporation after 25 years of service where he served as Vice President of Development for Storage Systems and was a member of the Chairman’s Senior Management Group. An engineer by training, Mr. Myers led a research and development facility with 1,600 scientists creating innovations in mass data storage and retrieval technologies.
Mr. Myers is very active in the state and local communities as a member of several other boards, including Science Foundation Arizona, Tucson Airport Authority, Women’s Foundation of Southern Arizona, National Advisory Board for the University of Arizona Science Center, and the Arizona State Commerce Global Network Board. He is the immediate past Chair of the Southern Arizona Leadership Council, an association of local CEOs focused on improving Tucson and Southern Arizona. Mr. Myers is recognized for his leadership and team-building skills, as well as his expertise in creating and managing organizational systems. He earned his bachelor of science degree in Mechanical Engineering at the University of Alabama.
Mrs. Cindy Parseghian is President of the Ara Parseghian Medical Research Foundation. Along with her husband, Michael, she is co-founder of the Ara Parseghian Medical Research Foundation, which they started in 1994 in an effort to find a cure for Niemann-Pick Type C disease, a rare and fatal genetic disorder that struck three of their four children. As President, Mrs. Parseghian has spearheaded a successful fundraising campaign raising more than $36 million in 16 years. Of the more than 400 rare disease organizations in America, the Parseghian Foundation has raised more funds than perhaps any other. She serves on a number of community and state and national boards including the National Institute of Neurological Disorders and Stroke Advisory Council, University of Notre Dame College of Science Advisory Council, Translational Genomics Inc. (TGen), The Critical Path Institute (C-Path), and San Miguel High School. Prior to founding the Ara Parseghian Medical Research Foundation, Mrs. Parseghian worked for seven years as President, CFO and Controller of MCS Telecommunications in Tucson. She earned a bachelor of business administration degree in Accounting at the University of Notre Dame, and a master’s degree in Management from the J.L. Kellogg Graduate School of Management at Northwestern University. Mrs. Parseghian has also successfully passed the CPA exam.
Dr. Alastair Wood received his medical degree from St Andrew’s University and Dundee Medical School in Scotland. He joined the faculty at Vanderbilt University School of Medicine in 1978 where he became tenured Professor of both Medicine and Pharmacology, and Attending Physician at Vanderbilt Medical School. He was Assistant Vice Chancellor for Clinical Research (1999-2004), and Associate Dean of Vanderbilt Medical School (2004-2006) before being appointed Emeritus Professor of Medicine and Emeritus Professor of Pharmacology in 2006. His current academic appointments are Professor of Medicine and Professor of Pharmacology at Weill Cornell Medical College in New York.
Dr. Wood has served on a number of editorial boards. He was a member of The New England Journal of Medicine editorial board (2004-2006); he was the Drug Therapy Editor of The New England Journal of Medicine from 1985 to 2004, and is currently on the editorial board of The British Journal of Clinical Pharmacology and The Scientist. He has previously served on the editorial boards of Clinical Pharmacology and Therapeutics and Biopharmaceutics and Drug Disposition. He authored the chapter in Harrison’s Principles of Internal Medicine on Adverse Drug Reactions from the 9th through the 15th edition.
Enrique Avilés joined Critical Path Institute (C-Path) in 2010 as Director of Data Standards, Management, and Technology. In 2012 Mr. Avilés was appointed as Chief Technology Officer for C-Path. Mr. Avilés has over 30 years of experience in information technology product development, data storage, and program management, and has led numerous projects to support large IT clients with a special focus on healthcare and banking IT systems. Since 2001, Mr. Avilés served as an executive at IBM in roles such as data storage product program management, storage product development, client technical support, and marketing. His executive experience also includes a two-year assignment working as the IBM technical advocate for a major healthcare provider in the United States in support of their electronic health records (EHR) system, one of the largest deployments of an EHR system.
In this role, his responsibility was to ensure that IBM hardware, software, and services used for the client’s EHR system operated reliably on a 24/7 basis. Additionally, Mr. Avilés was the IBM executive data storage advocate for one of the largest banks in Japan, traveling there multiple times each year to review product quality and new product development status with senior bank executives. Mr. Avilés received his Bachelor of Science degree in Mechanical Engineering from the Georgia Institute of Technology. He also received graduate certificates from the University of Arizona for an executive MBA program and from George Washington University for Project Management.
Mr. Steve Broadbent is responsible for the daily operations of the organization as well as developing and implementing C-Path’s strategy and goals. He manages the organization’s finances, human resources, facilities, information technology and personnel. In addition, he also oversees C-Path’s consortia efforts to ensure successful qualification of safety and efficacy biomarkers, disease progression models, patient-reported outcome instruments and other drug development tools.
Before joining C-Path, Mr. Broadbent was an IBM executive with nearly 31 years of experience in storage product development. He managed over 400 engineers in four countries with responsibility for architecting, developing, testing and supporting IBM’s largest and most complex disk storage systems—those used by top businesses and government agencies to store their most important data.
He earned a bachelor of science degree in electrical engineering from the University of Idaho and a master’s of business administration from the Eller College of Management at the University of Arizona. He is also a certified Project Manager.
Martha Brumfield, Ph.D., was recently named the interim president and chief executive officer of the Critical Path Institute. In this role, Dr. Brumfield will lead the institute in its mission to foster development of new evaluation tools, which accelerate medical product approval. Dr. Brumfield assumes the role of CEO after most recently serving as Critical Path Institute’s director of International & Regulatory Programs. In that position, she helped guide international program development and provided regulatory expertise to consortia.
She also leads her own consulting practice (Martha A. Brumfield LLC) focusing on concordance in global regulatory initiatives and regulatory science qualification programs. Other areas of focus in her practice include excellence in clinical trial conduct and pharmacovigilance, facilitation of scientific consortia and programs supporting patient access to medicines.
Dr. Brumfield brings 20 years of experience from Pfizer, Inc., most recently, as senior vice president of worldwide regulatory affairs and quality assurance. There, she led a global team that supported lifecycle pharmaceutical research, development and commercialization through creation and implementation of regulatory strategies and quality assurance oversight. Dr. Brumfield also played a key role in managing the broader company relationships with global regulators, trade associations, academics and others on regulatory policy issues. She served on corporate governance initiatives, including the planning and implementation of mergers and acquisitions and led her departments through these periods of significant change.
She participates in an advisory capacity to the Harvard Global Health Institute’s Multi-Regional Clinical Trial Center in developing a curriculum for potential Data and Safety Monitoring Board candidates from developing countries. She is also active with global nonprofits, including the Regulatory Harmonization Institute and GlobalMD, where she delivers educational workshops on regulatory and clinical trial topics in Asia. She has served on and contributed to the International Office of Medicine consensus committees, which were commissioned by U.S. FDA focusing on global regulatory systems.
Brumfield earned a bachelor of science degree and a master of science degree in Chemistry from Virginia Commonwealth University, a doctorate in organic chemistry from the University of Maryland and served as a post-doctoral fellow at the Rockefeller University.
For over two decades, the primary focus of Dr. Stephen Coons’s research has been the measurement of patient-reported outcomes. Prior to joining C-Path, Dr. Coons was a professor in the College of Pharmacy and the Mel & Enid Zuckerman College of Public Health at the University of Arizona.. In addition, he served as co-director of the Arizona Cancer Center’s Behavioral Measurements Shared Service.
After receiving a bachelor of science degree in Pharmacy from the University of Connecticut, he then completed a hospital pharmacy residency at the VA Medical Center in Phoenix and earned a master’s of science in Pharmacy, a master’s degree in Higher Education, and a doctorate in Pharmacy (Administrative and Behavioral Sciences) at the University of Arizona. His post-doctoral training in health outcomes research was completed at the University of California, San Diego. Previous academic appointments have been in the colleges of pharmacy, medicine and allied health professions at the University of Kentucky, and in the Division of Health Care Sciences at the UCSD School of Medicine. Dr. Coons is an emeritus professor at the University of Arizona UA and a fellow in the American Association of Pharmaceutical Scientists.
Dr. Debra Hanna joined Critical Path Institute as Associate Director for the Critical Path to TB Drug Regimens Consortium beginning June 1, 2011. Prior to joining C-Path, Dr. Hanna was a laboratory head and project team leader for 10 years within the Antibacterials Research Unit at Pfizer Worldwide Research and Development. During her time at Pfizer, Dr. Hanna led a dynamic research team focused on understanding pre-clinical pharmacodynamic and pharmacokinetic (PK/PD) relationships for novel antibacterial agents, spanning early discovery to Phase 2 development.
She championed the use of silico PK/PD modeling to drive the optimal compound and dose selection for new antibacterial agents. Dr. Hanna’s passion for tuberculosis research began during her postdoctoral fellowship at the University of California, San Diego, where she studied the impact of virulence genes for survival of Mycobacterium tuberculosis in the host lung. She received her doctorate in Microbiology from North Carolina State University, and her bachelor of science degree in Microbiology and Immunology from Colorado State University.
Dr. Lynn Hudson serves as the Chief Science Officer for Critical Path Institute. She received a bachelor of science degree in Biochemistry at the University of Wisconsin, a doctorate in Genetics and Cell Biology at the University of Minnesota, and post-doctoral training at Harvard Medical School and Brown University. For most of her career, Dr. Hudson has been a bench neuroscientist at the National Institutes of Health (NIH), where she directed the Office of Science Policy Analysis from 2006-2011. As a major source for policy analysis within NIH’s Office of the Director, her office covered a wide spectrum of sensitive and emerging issues and oversaw a number of programs, including the AAAS/NIH Science Policy Fellowship program, NIH’s contract with the National Academy of Sciences, and the Public-Private Partnership Program.
Her policy team’s awards cite contributions to NIH’s Congressional Justification, Biennial Report, implementation of the NIH Reform Act, Stem Cell Guidelines, and Comparative Effectiveness Research. Dr. Hudson conducted research in the National Institute of Neurological Disorders and Stroke (NINDS) intramural program, where she was Chief of the Section of Developmental Genetics for 16 years. Dr. Hudson received the NIH Merit Award for her discovery of the causative mutations in the neurologic disorder Pelizaeus-Merzbacher disease (PMD), and an NINDS Award for educational outreach efforts. Dr. Hudson’s research focused on defining the network of genes involved in the development of glial cells, with the goal of designing strategies to overcome glial dysfunction in inherited or acquired neurological diseases. She served as an officer for the American Society for Neurochemistry, an officer on the scientific advisory board of the PMD Foundation, and as an advisor for a number of granting agencies and disease foundations, including the National Multiple Sclerosis Society.
Dr. Jason Lundy joined Critical Path Institute in 2010 as the Assistant Director of the Patient-Reported Outcome (PRO) Consortium. After receiving his bachelor of science degree in Economics from Capital University, Dr. Lundy earned a master of science in Pharmacy and Health Care Administration from the University of Toledo and a doctorate in Pharmaceutical Economics, Policy and Outcomes Research from the University of Arizona.
While at the University of Arizona, Dr. Lundy conducted research assessing the psychometric equivalence of electronic PRO instruments. Upon completing his graduate studies, Dr. Lundy was employed by a large contract research organization, where he was primarily engaged in PRO assessments. Dr. Lundy works closely with Dr. Stephen Coons to support PRO and ePRO consortia activities and operations.
Dr. Klaus Romero is a native of Colombia and a Clinical Pharmacologist. He has worked as a Clinical Research Consultant for Astra-Zeneca Colombia, and as a Clinical Pharmacologist for the CIEO Foundation, a non-profit organization focused on drug safety research and pharmacovigilance in Colombia. In 2003, he planned, organized and implemented the Colombian National Police Health Services’ Pharmacovigilance system, which is still operating today. He is a member of the American College of Clinical Pharmacology and the American Society for Clinical Pharmacology and Therapeutics.
He has conducted research on endemic channels for non-steroidal anti-inflammatory drug-related gastropathy, antibiotic-related dysglicemia, pharmacoepidemiology, and patient education. Dr. Romero earned a medical degree from Javeriana University, and a master’s of science degree in Pharmacology from the Colombian National University, both in Bogotá Dr. Romero specialized in medical epidemiology at the El Bosque University, where he was part of the faculty as Assistant Professor of Pharmacology and as Instructor for the American Heart Association’s BLS, ACLS and ACLS-EP courses. He is fluent in English, Spanish, German and Portuguese, and he is the author of two books on drug toxicology, used by several schools of medicine in Colombia.
Dr. John Michael Sauer is a toxicologist by training with over 15 years of experience in drug discovery and development. He has been responsible for leading multiple functional areas across several pharmaceutical companies. He is dedicated to bringing quantitative translational science approaches to safety assessment, as well as transforming the way we use nonclinical safety data to drive clinical study design and data interpretation.
John Michael has over 100 scientific publications in the areas of toxicology, drug metabolism, clinical pharmacology, pharmacokinetics, and pharmacology.
Prior to joining C-Path in 2013, Dr. Sauer had the opportunity to play an individual contributor role at Eli Lilly where he participated in the development, registration, and commercialization of Strattera for the treatment of ADHD in children and adults, as well as supported many other discovery and development teams. He also played a pivotal leadership role in the transformation of Elan Pharmaceutical’s discovery and development strategies, including the incorporation of several quantitative translational science approaches. John Michael also gained operational and management experience in the Contract Research Organization (CRO) environment as the Site Scientific Head for the Covance Chandler site in Arizona.
Dr. Sauer received his undergraduate and Master’s degrees in Biomedical Sciences at Western Michigan University, and his Doctorate in Pharmacology and Toxicology from The University of Arizona.
Dr. Diane Stephenson is a neuroscientist by training with 30 years combined experience in academic neuroscience and drug discovery. She is passionate about translational science and is dedicated to the discovery of therapies to treat diseases of the nervous system. In her academic career, Dr. Stephenson focused her research on Amyotrophic Lateral Sclerosis and Alzheimer’s disease. While in industry she focused on drug discovery for Alzheimer’s disease, stroke and Parkinson’s disease.
Dr. Stephenson has over 55 scientific publications and six patents in the neuroscience area. Her specific areas of technical expertise include neuroimaging, neuropathology and animal model characterization. As an ambassador for public-private partnerships, she has initiated numerous external academic collaborations including worldwide alliances.
Prior to joining C-Path in 2011, Dr. Stephenson focused her attention on autism spectrum disorders and in 2007, she embarked on an effort with two Pfizer co-workers to garner support to address the unmet medical need in autism. As a result, in 2009 Pfizer became the first large pharmaceutical company to announce the formation of a dedicated unit devoted to discovering and developing new therapies for the treatment of autism.
Dr. Stephenson received her undergraduate degree in Biochemistry at University of California, Santa Barbara and her doctorate in Medical Neurobiology from Indiana University.